Last weekend, the Lupus Foundation of America attended the 13th International Congress on Systemic Lupus Erythematosus, which brought together lupus experts and advocates to learn about the latest science, research underway and groundbreaking advancements. The research findings and new discoveries discussed during the meeting demonstrate that we are moving closer to developing better treatments for people living with lupus. Here are some of the highlights...
Lupus Expert Shares Highlights of #LUPUS2019
Dr. Joan Merrill shares key takeaways of an “exciting” Congress meeting where lupus-focused researchers held discussions in smaller group settings to dissect what the most recent treatment advances and clinical trial data can teach us. She also explains why this meeting provided convincing evidence that there is a great amount of hope on the horizon.
Inside Lupus Research Team Reports on Research Important to You
The Lupus Foundation of America’s Inside Lupus Research℠ team was in San Francisco reporting and tweeting on research that matters most to you, much of which we contributed to as well! From an update on stem cell treatment of refractory lupus and new research studies from the Accelerating Medicine Partnership to how T cells contribute to lupus flares and the latest on the phase 2 trial of oral TYK2 inhibitor. Check out our brief summaries of some of the promising research shared at the meeting.
Lupus Foundation of America Gathers Leaders of World Lupus Federation
During the Congress, the World Lupus Federation (WLF), a coalition of organizations united to improve the quality of life for people with lupus, gathered for a meeting with members to discuss common issues within the lupus community around the world, and specifically, the importance of awareness, the need for emotional support and participation in clinical trials. The Lupus Foundation of America is proud to be a founding member of WLF and serve as the Federation’s Secretariat.
Study on Hydroxychloroquine Reveals Experiential Factors are Paramount to Treatment and Adherence
Findings from a new Lupus Foundation of America study on hydroxychloroquine (HCQ) treatment and adherence revealed experiential factors, such as medication impression and patient-reported symptom improvement, impact HCQ treatment adherence. Having a specialist as the primary lupus doctor and cultural factors can also play a role among certain racial groups.
 | 
